United Statesstate reportOR

Psychedelic research and access in

Oregon

Oregon remains the clearest operational US state model for legal, supervised psilocybin services outside FDA approval. Oregon Psilocybin Services, housed within the Oregon Health Authority Public Health Division, implements Ballot Measure 109, now codified at ORS chapter 475A.

Key Insights

  • 1

    Oregon is the only jurisdiction in this set with a verified live, state-regulated psilocybin services system for adults 21 and over.

  • 2

    The Oregon model is not FDA-approved treatment and should be described as regulated adult services, not conventional medical prescribing.

  • 3

    Access is real but still constrained by geography, local opt-outs, self-pay economics, and evolving rulemaking.

  • 4

    Oregon has become a major policy-research site, with OHSU’s federally funded OPEN work studying the real-world effects of legal community services.

  • 5

    Implementation is increasingly data-rich: licensing, complaint, emergency-contact, and client/service-centre reporting systems are now built into the programme.

Research Snapshot

Deep report

Blossom currently tracks 8 psychedelic clinical trials with verified sites in Oregon, including 2 active studies.

Active trials
2

Verified state-linked study sites

Total trials
8

Linked trial records

Stakeholders
11

9 physical, 2 jurisdiction-linked

Events
0

Linked state-level events

Top Compounds

  • Psilocybin(4)
  • Ketamine(1)
  • LSD(1)
  • MDMA(1)

Top Study Topics

  • Anxiety Disorders(2)
  • Treatment-Resistant Depression (TRD)(2)
  • Chronic Pain(1)
  • Healthy Volunteers(1)
  • Major Depressive Disorder (MDD)(1)

Active Trial Preview

View linked trials →

Access and Payment

Ketamine/esketamine access; no state-regulated classical psychedelic pathway

Oregon is the only jurisdiction in this set where verified legal psilocybin access is live today. OHA states that clients do not need to live in Oregon, must be 21 or over, do not need a prescription or referral, and must complete a preparation session before an administration session at a licensed service centre. This access sits alongside, not inside, conventional psychiatric prescribing.

Research signal

Not Reviewed

Oregon is now also a policy-research jurisdiction. 3 million National Institute on Drug Abuse award to study the safety and effectiveness of state-regulated psilocybin services in community settings, led through the Oregon Psychedelic Evaluation Nexus.

Ketamine / esketamine

Available

Oregon is the only jurisdiction in this set where verified legal psilocybin access is live today. OHA states that clients do not need to live in Oregon, must be 21 or over, do not need a prescription or referral, and must complete a preparation session before an administration session at a licensed service centre.

No state service model

Not Available

No state-regulated psilocybin, MDMA or natural-medicine service model is verified for Oregon.

Classical psychedelics

Not Available

Oregon’s framework keeps evolving. Local governments may refer ordinances to voters to prohibit psilocybin manufacturers and service centres in their jurisdictions, and OHA must stop licensing affected premises until the next statewide general election process resolves the measure.

Reimbursement / payment

Limited

Oregon has state-specific Medicaid or payer material relevant to esketamine, but current plan criteria should be rechecked before relying on coverage details.

Policy and Access Timeline

State-level bills, laws, pilots, agency actions, and reimbursement details that shape real-world access.

  1. 22 May 2025

    ActiveTask Force

    HB 2387 was signed, leading to 2026 dual-licensure and reporting changes

    HB 2387 was signed, leading to 2026 dual-licensure and reporting changes.

    Oregon
    OLIS signed-bills listing; OHA rulemaking letter; OHA guidance→

  2. 1 Jan 2025

    ActiveTask Force

    SB 303 client and service-centre data reporting requirements began

    SB 303 client and service-centre data reporting requirements began.

    Oregon
    OHA Oregon Psilocybin Services overview→

  3. 1 Nov 2020

    ActiveLaw

    Oregon voters passed Ballot Measure 109, creating the statutory framework now codified...

    Oregon voters passed Ballot Measure 109, creating the statutory framework now codified in ORS chapter 475A.

    Oregon
    OHA Oregon Psilocybin Services overview→

Advocacy and Nonprofit Coverage

These organizations have jurisdiction-level policy, advisory, or nonprofit relevance in Oregon. They are separate from physical office locations.

Healing Advocacy Fund
Policy Campaign CoalitionSubnational / State-LevelExplicit Psychedelic FocusPolicy Campaign

Healing Advocacy Fund is a state-focused psychedelic access organization serving patients, clinicians, and local stakeholders in Oregon and Colorado, with some publicly stated interest in New Mexico as that state develops a regulated model. Its work emphasizes implementation support, safety, affordability, and practical access, including patient education, clinician resources, adverse-event reporting, and policy changes meant to improve how regulated psilocybin therapy works on the ground. Likely collaboration areas include program evaluation, clinical training, implementation research, patient navigation, reimbursement and affordability work, and policy design support for regulated access models.

Medical Access Pathways / Health System Implementation Policy / Public Education and Awareness / Controlled Substance / Scheduling Reform

Healing Advocacy Fund - Official Website
Oregon Psilocybin Advisory Board
Caucus / Working GroupSubnational / State-LevelExplicit Psychedelic FocusRegulator Public Agency Role

This is an Oregon state advisory board serving the public psilocybin services system, with a primary audience of Oregon Health Authority staff, regulators, service-system stakeholders, and the public participating in meetings or comment processes. Its activity centers on evidence review and recommendations about psilocybin service rules, safeguards, standards, and operational controls, so it is best understood as an implementation-focused policy body rather than an advocacy campaign. For collaboration, researchers can contribute evidence syntheses, clinicians can inform safety and standards discussions, and patient or community groups can provide lived-experience input on access, equity, and practical service design.

Health System Implementation Policy / Controlled Substance / Scheduling Reform / Research and Evidence Policy Briefing / Public Education and Awareness

Oregon Health Authority - Psilocybin Advisory Board meetings

Regulatory Status

Oregon remains the clearest operational US state model for legal, supervised psilocybin services outside FDA approval. Oregon Psilocybin Services, housed within the Oregon Health Authority Public Health Division, implements Ballot Measure 109, now codified at ORS chapter 475A. OPS began accepting licence applications on 2 Jan 2023, and licensed psilocybin service centres began opening in summer 2023. This is not FDA-approved treatment. Oregon’s access route is a state-regulated adult services model for people aged 21 and over; OHA states that no prescription or medical referral is required, and access occurs through licensed service centres with licensed facilitators. Federal law still matters, and OHA itself notes continuing federal constraints around business support and related services.

Medical Access Summary

Oregon is the only jurisdiction in this set where verified legal psilocybin access is live today. OHA states that clients do not need to live in Oregon, must be 21 or over, do not need a prescription or referral, and must complete a preparation session before an administration session at a licensed service centre.[1][2][3]

This access sits alongside, not inside, conventional psychiatric prescribing. Ketamine and FDA-approved esketamine remain separate ordinary medical routes. Oregon’s state-regulated psilocybin services should not be described as medical treatment approved by FDA. On the supply side, OHA’s 2024 year-in-review reported 345 licensed facilitators, 31 licensed service centres, 11 licensed manufacturers, one licensed laboratory, 724 worker permits, and 22 approved training programmes as of 31 Dec 2024.[2][4][1]

Cost and reimbursement remain practical constraints. Oregon’s Office of Economic Analysis noted that the 15% tax applies to psilocybin products, not the whole session cost, and that most of the overall cost goes to operational expenses and facilitator time. That strongly suggests continued out-of-pocket access rather than broad reimbursement, and This source pass did not verify insurer coverage for state-regulated psilocybin services.[2][1][5]

Local Research Map

Mapped trial sites, physical stakeholders, and events linked to Oregon.

Policy and Access Context

Oregon’s framework keeps evolving. Local governments may refer ordinances to voters to prohibit psilocybin manufacturers and service centres in their jurisdictions, and OHA must stop licensing affected premises until the next statewide general election process resolves the measure. That local opt-out structure materially shapes access geography.[1][2][3]

OPS also now runs a more formalised data and oversight system. OHA states that, beginning 1 Jan 2025, service centres must collect and submit specified client-level and service-centre-level data under SB 303, with quarterly aggregated reporting through the TLC system. In parallel, HB 2387 was signed in 2025 and, from 1 Jan 2026, allows facilitators who also hold certain Oregon professional licences to provide healthcare or behavioural-health services during preparation and integration sessions; related 2025 rulemaking also added veteran-status data collection and psilocin labelling requirements.[4][2][3]

Oregon’s broader drug-possession environment is no longer the Measure 110 model of early 2021–2024. HB 4002 increased penalties for unlawful possession of controlled substances from 1 Sep 2024, even while separate licensed psilocybin conduct remains authorised under ORS 475A. That distinction is essential for access and enforcement reporting.[2][5][4]

Research Focus

Oregon is now also a policy-research jurisdiction. In Feb 2026, OHSU announced a five-year, $3.3 million National Institute on Drug Abuse award to study the safety and effectiveness of state-regulated psilocybin services in community settings, led through the Oregon Psychedelic Evaluation Nexus. OHSU said the initiative is the first federally funded work to study legal psychedelic services delivered in community settings.[1][2][3]

The OHSU story also provides unusually concrete scale indicators: researchers had already gathered preliminary data from more than 300 Oregon psilocybin-service clients willing to participate and aimed to enrol at least 1,600 participants over five years. ClinicalTrials.gov search results also point to Oregon-based studies including a Portland low-income group psilocybin-assisted therapy feasibility study and a study on psilocybin microdosing plus meditation.[2][1][3]

Implementation Context

Oregon has the most developed implementation machinery in this set. OPS sits inside OHA’s Public Health Division; it licenses and regulates manufacturers, service centres, facilitators and laboratories, maintains licensing and compliance data, and now receives quarterly service-centre reporting. OHA’s 2024 year-in-review recorded 55 complaints, two licence application denials, five final orders for administrative violations, 18,424 psilocybin products sold to clients for administration sessions, and 103 reported emergency-service contacts by 31 Dec 2024.[1][2][3]

Rulemaking remains active. OHA’s administrative-rules page states that a temporary rule related to service-centre location requirements became permanent on 22 Jan 2026. OPS also convened a 2026 potency workgroup after licensee concerns about products with high psilocin content being used in lower-dose sessions. Facilitator scope remains formally non-directive, with only limited dual-licence health-service activity permitted in preparation and integration settings.[4][3][2]

Ecosystem Context

Oregon’s ecosystem is now layered: regulator, academic evaluators, service businesses, training programmes, and advisory structures all exist in public view. OHA’s 2024 year-in-review highlights continuing activity by the Oregon Psilocybin Advisory Board and subcommittees, licensee lunch forums, new operational resources, and public listening sessions.[1][2][3]

On the research side, OHSU and OPEN are the clearest institutional anchors. OHSU’s integrative-health research pages also identify its SNAP lab as working on MDMA- and psilocybin-related research themes, and the 2026 NIDA award positions Oregon as a nationally important natural experiment in community-setting supervised psilocybin services.[4][1][3]

Key Milestones

Nov 2020
Oregon voters passed Ballot Measure 109, creating the statutory framework now codified in ORS chapter 475A.
2 Jan 2023
OPS began accepting licence applications.
Summer 2023
Licensed psilocybin service centres began opening to clients.
1 Jan 2025
SB 303 client and service-centre data reporting requirements began.
22 May 2025
HB 2387 was signed, leading to 2026 dual-licensure and reporting changes.
22 Jan 2026
Updated service-centre location rules became permanent.
12 Feb 2026
OHSU announced the first federal research award to study legal psychedelic community services.

Future Outlook

Over the next 12 to 24 months, Oregon will probably generate more implementation evidence than any other state. The highest-value signals will be quarterly data releases, safety and utilisation patterns, dual-licensure uptake after HB 2387, and whether local opt-out geography continues to constrain supply.[1][2][3]

On the access side, the main open question is not legality but affordability and service distribution. Oregon has proved that legal supervised psilocybin services can operate; the next phase is whether the system becomes more geographically available, more professionally integrated, and more empirically legible to payers, policymakers and researchers. Public reimbursement for state-regulated psilocybin services remains unverified and should be treated cautiously.[2][4][5]

Sources and Review

Last updated 18 May 2026. Source links come from the subnational report.

  1. 1OHA Access Psilocybin Services
  2. 2OHA Oregon Psilocybin Services overview
  3. 3OHSU News
  4. 4OLIS signed-bills listing; OHA rulemaking letter; OHA guidance
  5. 5OPS 2024 Year in Review
  6. 6ORS 475A.718